tiprankstipranks
AxoGen reports Q4 adjusted EPS (3c), consensus (11c)
The Fly

AxoGen reports Q4 adjusted EPS (3c), consensus (11c)

Reports Q4 revenue $36.2M, consensus $36.2M. "We are pleased with our solid performance this quarter and the second half of 2022 which saw improved surgical capacity and predictability in hospitals," commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. "We believe the combination of an improved hospital operating environment and commercial execution, backed by our high-quality portfolio of clinical data provides a solid foundation for long term, sustainable growth."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AXGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles